Professor Christine Harrison

Professor of Childhood Cancer Cytogenetics

Email: christine.harrison@ncl.ac.uk
Telephone: +44 (0) 191 208 2237
Address: Leukaemia Research Cytogenetics Group Wolfson Childhood Cancer Research Centre Northern Institute for Cancer Research Newcastle University
Level 6, Herschel Building
Brewery Lane
Newcastle-upon-Tyne
NE1 7RU

Background

Christine J Harrison PhD FRCPath FMedSci

Professor of Childhood Cancer Cytogenetics

Leukaemia Research Cytogenetics Group

Wolfson Childhood Cancer Research Centre

Northern Institute for Cancer Research,

Level 6, Herschel Building

Newcastle University,

Newcastle upon Tyne

Phone: 0191 208 2237

email: christine.harrison@newcastle.ac.uk

Professor of Childhood Cancer Cytogenetics, Newcastle University

Director, Centre for Haematological Oncology, Newcastle University

Director, Leukaemia Research Fund Cytogenetics Group

Fellow, Academy of Medical Sciences

Fellow, Royal College of Pathologists

Newcastle University, Vice Chancellor Academic Distinction Award 2017

Review panel, European Research Council

Review Panel, GILEAD

Review Panel, INcA

Review panel, Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO).

Research

The remit of my research is to improve outcome for patients with acute leukaemia through genetics in UK treatment trials, by characterisation of existing and discovery of novel genetic changes. I have over 30 years’ experience in planning and leading research activities of national/international repute in the area of cytogenetics/genetics of haematological malignancies. I was responsible for the initiation of a database for the cytogenetics of acute leukaemia in 1988, when the importance of chromosomal abnormalities in risk stratification for treatment was becoming evident. This has now developed into a large-scale collection of cytogenetic and genetic data, containing information on more than 28,000 UK patients, which is renowned to be one of the best leukaemia genetics research resources in the world. Some of the most recent analyses from these data have identified new cytogenetic-based risk categories in childhood and adult acute leukaemia, which have resulted in changes in clinical practice.

I have a passion for the development of new technologies. In the 1980’s, I pioneered studies on the scanning electron microscopy of metaphase chromosomes to provide increased resolution for detailed analysis at the structural level. The demand for images from these investigations continues to this day.

From studies on deletions of the long arm of chromosome 6 (6q) in acute leukaemia, I was one of the early pioneers of chromosome mapping using fluorescence in situ hybridisation (FISH)

I was responsible for the development of FISH for the detection of chromosomal abnormalities of prognostic significance in UK acute leukaemia clinical treatment trials. FISH is now used routinely in UK and has been adopted into trial protocols in Europe and internationally. This approach led to the discovery of novel chromosomal abnormalities for which modified treatment has significantly improved survival.

Within my group we provided early development of procedures for array-based comparative genomic hybridisation (aCGH) in acute leukaemia, which now is widely used for the detection of chromosomal imbalances, not only in leukaemia but a wide range of other cancers. Using this in association with other procedures, we have identified novel chromosomal abnormalities with potential as molecular targets for therapy. My current interests involve the application of next-generation sequencing to search for novel significant mutations in acute leukaemia. Understanding of the role of genetics in the improved survival of leukaemia patients is my ultimate aim.

Selected publications

O’Connor, D., Enshaei, A., Bartram, J., Hancock, J., Harrison, C.J., Hough, R., Samarasinghe, S., Schwab, C., Vora, A., Wade, R., Moppet, J., Moorman, A.V., Goulden, N. (2018) Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia. J Clin Oncol 36(1): 34-43
Schwab, C., Nebral, K., Chilton, L., Leschi, C., Waanders, E., Boer, J.M., Zaliova, M., Sutton, R., Öfverholm, I.I., Ohki, K., Yamashita, Y., Groeneveld-Krentz, S., Froňková, E., Bakkus, M., Tchinda, J., da Conceição Barbosa, T., Fazio, G., Mlynarski, W., Pastorczak, A., Cazzaniga, G., Pombo-de-Oliveira, M.S., Trka, J., Kirschner-Schwabe, R., Imamura, T., Barbany, G., Stanulla, M., Attarbaschi, A., Panzer-Grümayer, R., Kuiper, R.P., den Boer, M. L. Cavé, H., Moorman, A. V., Harrison, C.J.^#, Strehl, S.^# (^#Joint senior authors) (2017) Intragenic amplification of PAX5: A novel subgroup in B-cell precursor acute lymphoblastic leukemia? Blood Advances
Russell, L.J., Jones, L., Enshaei, A., Tonin, S,, Ryan, S.L., Eswaran, J., Nakjang, S., Papaemmanuil, E., Tubio, J.M., Fielding, A.K., Vora, A., Campbell, P.J., Moorman, A.V., Harrison, C.J. (2017) Characterisation of the Genomic Landscape of CRLF2-rearranged Acute Lymphoblastic Leukemia. Genes, Chromosomes, Cancer 56(5): 363-72
Chilton, L.C., Harrison, C.J., Ashworth, I., Murdy, D., Burnett, A.K., Grimwade, D., Moorman, A.V., Hills, R (2017) Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia (AML). Leukemia 31(5):1234-1237
O’Connor, D., Moorman, A.V., Wade, R., Hancock, J., Tan, R.M.R., Bartram, J., Moppett, J., Schwab, C., Patrick, K., Harrison, C.J., Hough, R., Goulden, N., Vora, A., Samarasinghe, S. (2016) Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. J. Clin Oncol. 35(6): 660-7
Chilton, L., Hills, R.K., Burnett, A.K., Harrison^,C.J. (2016) The prognostic significance of trisomy 4 in acute myeloid leukaemia (AML) is dependent on age and additional abnormalities. Leukemia 30(11): 2264-7
Ryan, S.L., Matheson, E., Grossmann, V., Sinclair, P., Bashton, M., Schwab, C., Towers, W., Partington, M., Elliott, A., Minto, L., Richardson, S., Rahman, T., Keavney, B., Skinner, R., Bown, N., Haferlach, T., Vandenberghe, P., Haferlach, C., Santibanez-Koref, M., Moorman, A.V., Kohlmann, A., Irving, J.A.E.^,Harrison, C.J. (2016) The role of the RAS pathway in iAMP21-ALL Leukemia (in press)
Moorman, A.V., Enshaei, A., Schwab, C., Chilton, L., Elliott, A., Richardson, S., Hancock, J., et al, Goulden, N., Vora, A. and Harrison, C.J.* (2014) A novel integrated cytogenetic and genomic classification refines risk stratification in paediatric acute lymphoblastic leukaemia (ALL). Blood 124 (9): 1434-44
Li, Y., Schwab, C., Ryan, S., Papaemmanuil, E., Heerema, N.A., Young, B.D., Stephens, P.J., et al, Stratton, M.R., Campbell, P.J.*Ϯ,Harrison, C.J.* Ϯ (2014) Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508 (7494): 98-102
Russell, L.J., Enshaei, A., Bentley, H., Fielding, A.K., et al, Goulden, N., Vora, A., Moorman, A.V., Harrison, C.J.* Ϯ (2014) IGH@translocations are prevalent in teenagers and young adults with ALL and are associated with a poor outcome. J Clin Oncol 32 (14): 1453-62
Harrison, C.J. Ϯ, Moorman, A.V., Schwab, C., Carroll, A.J., Raetz, E.A., Devidas, M., et al, Hunger, S.P., Heerema, N.A., Haas, O.A. (2014) An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28 (5): 1015-21
Moorman, AV., Robinson, H. Schwab, C., Richards, SM., Hancock, J., Mitchell, CD., Goulden, N., Vora, A., Harrison, C.J.* (2013) Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 Trials. J Clin Oncol 31 (27): 3389-96.
Moorman, A.V., Schwab, C., Ensor, H.M., Russell, L.J., et al, Patel, B., Rowe, J.M., Tallman, M., Goldstone, A.H., Fielding, A.K.,Harrison, C.J.* (2012) IGH@ translocations, CRLF2 deregulation and micro-deletions in adolescents and adults with acute lymphoblastic leukemia (ALL). J. Clin Oncol 30 (25); 3100-8
Rand, V., Russell, L.J., Schwab, C., et al, Ryan, S., Robinson, H., et al, Sinclair, P., Moorman, A.V., Strefford, J.C.*, Harrison, C.J.* Ϯ(2011) Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 117 (25); 6848-55
Sinclair, P.B., Parker, H., An, Q., Rand, V., Ensor, H., Harrison, C.J.* Ϯ, Strefford, J.C.* (2011) Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy. Hum Mol Genet 20 (13); 2591-602
Moorman, A.V., Ensor, H.M., Richards, S.M., Chilton, L., Schwab, C., Kinsey, S., Vora, A., Mitchell, C.D., Harrison, C.J.* (2010) The prognostic impact of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia. Lancet Oncology 11 (5); 429-38
Harrison, C.J.Ϯ, Hills, R.K., Moorman, A.V., Grimwade, D.J., et al, Webb, D.K.H., Wheatley, K., de Graaf, S.S.N., van den Berg, E., Burnett, A.K., Gibson, B.E.S. (2010) Cytogenetics of childhood acute myeloid leukemia: 729 patients in UK Medical Research Council treatment trials, AML 10 and 12. Journal of Clinical Oncology 28 (16); 2674-81
Russell, L.J., Capasso, M., Vater, I., Akasaka, T., Bernard, O.A., et al, Nguyen-Khac, F., Moorman, A.V., Schwab, C., Dyer, M.J., Siebert, R., Harrison, C.J.*Ϯ (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B cell precursor acute lymphoblastic leukemia. Blood 114 (13); 2688-98.
Russell, L.J., De Castro, D.G., Griffiths, M., Telford, N., Bernard, O., Panzer-Grümayer, R., Heidenreich, O., Moorman, A.V., Harrison, C.J.*Ϯ (2009) A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia; 23 (3); 614-617.
Sulong, S., Moorman, A.V., Irving, J.A.E., Strefford, J.C., et al, Bown, N.P., Bailey, S., Hall, A.G. and Harrison, C.J.* (2009) A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukaemia reveals homozygous deletion, haplo-insufficiency, copy number neutral loss of heterozygosity and association with specific cytogenetic subgroups. Blood; 113 (1); 100-107.
Russell, L.J., Akasaka, T., Majid, A., et al, Moorman. A.V., Ross, F., Mazzullo, H., Strefford, J.C., Siebert, R.*, Dyer, M.J.*, Harrison, C.J*Ϯ. (2008) t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 111 (1); 387-391
Akasaka, T., Balasas, T., Russell, L.J., Haas, O.A., et al, Strefford, J.C., Harrison, C.J.*Ϯ, Siebert, R.*, Dyer, M.J.* (2007). Five members of the CEBP transcription factor family are targeted by recurrent IGH-translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 109 (8); 3451-3461
Moorman, A.V., Richards, S.M., Robinson, H.M., Strefford, J.C., Gibson, B.E., Kinsey, S.E., Eden, O.B., Vora, A.J., Mitchell, C.D, Harrison, CJ.* (2007) Prognosis of children with acute lymphoblastic leukaemia (ALL) and intra-chromosomal amplification of chromosome 21 (iAMP21). Blood 109 (6); 2327-2330.

Publications

Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 2016, 127(18), 2214-2218.
Ciardullo C, Willmore E, Enshaei A, Zhou P, Rand V, Soundararajan M, Hall A, Harrison C, Eswaran J. BACH2 and BCL6 Cooperatively Fuction as Tumour Suppressors in CLL. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Ferrata Storti Foundation.
Milani G, Durinck K, Matthijssens F, Peirs S, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Li YL, Schwab C, Raimondi S, De Moerloose B, Benoit Y, Berx G, Harrison C, Basso G, Cave H, Sutton R, Asnafi V, Mullighan C, Meijerink J, Loh M, Van Vlierberghe P. Genetic characterization and therapeutic targeting of MYC translocated pediatric T-cell acute lymphoblastic leukemia. In: AACR Special Conference. 2016, Atlanta, GA, USA: American Association for Cancer Research.
Ciardullo C, Zhou P, Willmore E, Harrison CJ, Hall A, Eswaran J, Soundararajan M. Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia. In: XXXVI World Congress of the International Society of Hematology. 2016, Glasgow: Wiley-Blackwell.
Ciardullo C, Willmore E, Zhou P, Rand V, Harrison C, Hall A, Eswaran J, Soundararajan M. Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Fondazione Ferrata Storti.
Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2016, 128(7), 911-922.
Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ. The role of the RAS pathway in iAMP21-ALL. Leukemia 2016, 30, 1824-1831.
Wade MA, Sunter NJ, Fordham SE, Long A, Masic D, Russell J, Harrison CJ, Rand V, Elstob C, Bown N, Rowe D, Lowe C, Cuthbert G, Bennett S, Crosier S, Bacon CM, Onel K, Scott K, Scott D, Travis LB, May FEB, Allan JM. c-MYC is a radiosensitive locus in human breast cells. Oncogene 2015, 34, 4985-4994.
Sinclair P, Cheng J, Raninga P, Hanna R, Hollern S, Enshaei A, Blair H, Nakjang S, Ryan S, Eswaran J, Buechler L, Heidenreich O, Harrison C. A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM1. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
Gabriel AS, Enshaei A, Taylor J, Erhorn A, Schwab C, Rai L, Fielding A, Goulden N, Vora A, Harrison CJ, Moorman AV. Age specific incidence of partner gene and secondary abnormalities in MLL positive acute lymphoblastic leukaemia (ALL). In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Ferrata-Storti Foundation/European Hematology Association.
Russell LR, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
Moorman AV, Irving J, Enshaei A, Parker CA, Sutton R, Kuiper R, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V. Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia. In: 20th Congress of the European Hematology Association. 2015, Vienna: Ferrata Storti Foundation.
Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015, 10(8), 717-726.
Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA.
O'Connor D, Bartram J, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
Bartram J, O'Connor D, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD: Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
Nicholson L, Evans C, Matheson E, Minto L, Keilty C, Sanichar M, Case M, Schwab C, Williamson D, Rainer J, Harrison C, Kofler R, Hall AG, Rednern CPF, Wheaton AD, Irving JAE. Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. British Journal of Haematology 2015, 171(4), 595–605.
Lana T, de Lorenzo P, Bresolin S, Bronzini I, den Boer ML, Cave H, Fronkova E, Stanulla M, Zaliova M, Harrison CJ, de Groot H, Valsecchi MG, Biondi A, Basso G, Cazzaniga G, te Kronnie G. Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2015, 29(10), 2107-2110.
Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, LaStarza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J. Targeted Sequencing Identifies Association Between IL7R-JAK Mutations And Epigenetic Modulators In T-Cell Acute Lymphoblastic Leukemia. Haematologica 2015, 100, 1301-1310.
Vijayakrishnan J, Henrion M, Moorman AV, Fiege B, Kumar R, da Silva MI, Holroyd A, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Bartram CR, Schrappe M, Greaves M, Hemminki K, Harrison CJ, Stanulla M, Houlston RS. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Scientific Reports 2015, 5, 15065.
Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, Calado DP, Harrison CJ, Vormoor J. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 2015, 29(8), 1623-1631.
Chilton L, Hills RK, Burnett AK, Harrison CJ. The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities. Leukemia 2016, 30(11), 2264–2267.
Vijayakrishnan J, Kumar R, Henrion MYR, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jockel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia 2017, 31(3), 573-579.
Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood & Cancer 2017, 64(6), e26351 1-4.
Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 2017, 31(5), 1234–1237.
Dixon ZA, Nicholson L, Zeppetzauer M, Matheson E, Sinclair P, Harrison CJ, Irving JAE. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response. Haematologica 2017, 102(4), 736-745.
Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, De Moerloose B, Schwab C, Vettenranta K, Harrison CJ, Knuutila S, Schouten J, Lammens T, Savola S. Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia. Journal of Molecular Diagnostics 2017, 19(5), 659-672.
Enshaei A, OConnor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, Moorman AV, Goulden N. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2017, 36(1), 34-43.
Schwab CJ, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Zaliova M, Sutton R, Ofverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Fronkova E, Bakkus M, Tchinda J, Conceicao-Barbosa T, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grumayer R, Kuiper RP, den-Boer ML, Cave H, Moorman AV, Harrison CJ, Strehl S. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances 2017, 1, 1473-1477.
Laing AA, Harrison CJ, Gibson BES, Keeshan K. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Experimental Hematology 2017, 54, 40-50.
O'Connor D, Moorman AV, Wade R, Hancock J, Tan RMR, Bartram J, Moppett J, Schwab C, Patrick K, Harrison CJ, Hough R, Goulden N, Vora A, Samarasinghe S. Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology 2017, 35(6), 660-667.
Andersson A, Moorman AV, Harrison CJ, Mullighan C. Acute lymphoblastic leukaemia. In: Tosi S; Reid AG, ed. The Genetic Basis of Haematological Cancers. Chichester: Wiley Blackwell, 2016, pp.223-264.
Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2016, 56(5), 363-372.
Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic Myeloid Leukemia: Reminiscences And Dreams. Haematologica 2016, 101(5), 541-558.
Harrison CJ, Schwab C. Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukaemia. European Journal of Medical Genetics 2016, 59(3), 162-165.
La Starza R, Barba G, Demeyer S, Pierini V, Di Giacomo D, Gianfelici V, Schwab C, Matteucci C, Vicente C, Cools J, Messina M, Crescenzi B, Chiaretti S, Foà R, Basso G, Harrison CJ, Mecucci C. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica 2016, 101(8), 951-958.
Harrison CJ. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood 2015, 125(9), 1383-1386.
Johansson B, Harrison CJ. Acute myeloid leukemia. In: Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, Fourth Edition. Wiley Blackwell, 2015, pp.62-125.
Harrison CJ. Advances in the Genetics of Childhood Leukaemia: a Success Story. In: 20th International Chromosome Conference. 2015, Canterbury, UK: Springer.
Russell LJ, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, Zapotocky M, De Moerloose B, Fynn A, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Forestier E, Salgado C, Balwierz W, Popa A, Rubnitz J, Raimondi S, Gibson B. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group. Journal of Clinical Oncology 2015, 33(36), 4247-4258.
Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica 2018, 103, 634-644.
Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2018, 9(1), 1340.
Degryse S, Bornschein S, De Bock CE, Leroy E, Bempt MV, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood 2018, 131(4), 421-425.
Furness CL, Mansur MB, Weston VJ, Ermini L, van Delft FW, Jenkinson S, Gale R, Harrison CJ, Pombo-de-Oliveira MS, Sanchez-Martin M, Ferrando AA, Kearns P, Titley I, Ford AM, Potter NE, Greaves M. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. Leukemia 2018.
Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, De Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. Leukemia 2018, 32(3), 809-819.